What can be expected from the East Asian pharmaceutical market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.
Our 132-page report provides 67 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall regional market and national level. You will see financial results, an interview, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2016-2026 and other analyses show you commercial prospects Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.
See revenue forecasts for the leading submarkets and indications How will submarkets perform to 2026? Our study forecasts revenues in Japan, Taiwan and Korea for the following drug classes: • Generic Drugs • Originator Drugs • OTC Drugs • Biosimilars
Leading companies and potential for market growth Overall revenue for the East Asian pharmaceutical market will reach $121.5bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. The ageing of the population in each country results in strong opportunities for increased pharmaceutical sales.
Our work analyses the key companies in the market. See Visiongain’s analysis of 13 leading companies, including these: • Takeda • Astellas Pharma • Otsuka Pharmaceutical • Daiichi Sankyo • Eisai Co. • Standard Chem and Pharma Co. • Chunghwa Chemical and Pharmaceutical • Yung Shin • TWi Biotechnology • OBI Pharmaceutical • Daewoong Pharmaceutical • Samsung Bioepis • Celltrion
A company profile gives you the following information where available: • Discussion of a company’s activities and outlook • Company news relevant to the market
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the East Asian Pharmaceutical industry? Our new report discusses issues and events affecting the East Asian pharmaceutical market. You will find discussions, including qualitative analyses: • Trends driving increased pharmaceutical demand • Government programmes to reduce pharmaceutical spending
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the East Asian Pharmaceutical Market 2016-2026 report helps you In summary, our 132-page report gives you the following knowledge: • Revenue forecasts to 2026 for the East Asian pharmaceutical market – discover the industry’s prospects, finding promising places for investments and revenues • Revenue forecasts to 2026 for the leading national markets – Japan, Taiwan and Korea • Revenue forecasts to 2026 for submarkets in each nation – discover prospects for leading generics, originator drugs, OTC products and biosimilars in each country. Identify the key trends driving and restraining growth in the market, including government policy and economic conditions relevant to the market. • Assessment of 13 leading companies – revenue (where available), news and upcoming product releases • Discussion of what stimulates and restrains the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the East Asian pharmaceutical market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 East Asian Pharmaceutical Market Overview 1.2 East Asian Pharmaceutical Market Report Segmentation 1.3 Why You Should Read This Report? 1.4 How This Report Delivers 1.5 Key Questions Answered by This Analytical Report 1.6 Who is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Visiongain Reports 1.10 About Visiongain 1.11 Exchange Rates
2. Introduction to the East Asian Pharmaceutical Market 2.1 National Market Definitions 2.1.1 Japan 2.1.2 Taiwan 2.1.3 Korea 2.2 Other Pharmaceutical Market Definitions 2.2.1 Originator Drugs 2.2.2 Generic Drugs (Generics) 2.2.3 OTC (Over-The-Counter) 2.2.4 Biosimilars 2.3 Introduction to the Global Pharmaceutical Market: A Brief Overview 2.4 Pharmaceutical Approval Regulations 2.4.1 Japan 2.4.2 Taiwan 2.4.3 Korea 2.5 The East Asian Pharmaceutical Market Forecast, 2016-2026
3. The Japanese Pharmaceutical Market 3.1 The Japanese Healthcare System 3.1.1 Costing and Healthcare Delivery 3.1.2 Increasing Generic Penetration: A Matter of Government Policy 3.1.3 Health Technology Assessments 3.2 The Japanese Pharmaceutical Market 2014 and 2015 3.2.1 The Japanese Pharmaceutical Market Forecast, 2016-2026 3.3 The Japanese Pharmaceutical Market 2016-2026: Submarket Shares 3.4 The Japanese Generic Drugs Market 2014 3.4.1 Public Perception Of Generics In Japan 3.4.2 The Japanese Generic Drugs Market Forecast, 2016-2026 3.5 The Japanese Originator Drugs Market 2014 3.5.1 The Japanese Originator Drugs Market Forecast, 2016-2026 3.6 The Japanese OTC Drugs Market 2014 and 2015 3.6.1 The Japanese OTC Drugs Market Forecast, 2016-2026 3.7 The Japanese Biosimilar Drugs Market 2014 and 2015 3.7.1 The Japanese Biosimilar Drugs Market Forecast, 2016-2026
4. Qualitative Analysis of the Japanese Pharmaceutical Market 4.1 SWOT Analysis of The Japanese Pharmaceutical Market, 2016-2026 4.1.1 Strengths 4.1.1.1 Affinity for Branded Products Helping Maintain Revenues 4.1.1.2 High Utilisation of Healthcare Facilities 4.1.1.3 Ageing Population Driving Demand 4.1.2 Weaknesses 4.1.2.1 Reduced Profit Margins Due to Government Pricing 4.1.2.2 Increasing Penetration of Generics Eroding Off-Patent Originator Revenues 4.1.2.3 Restrictions of the OTC Market and Low Consumer Desire 4.1.3 Opportunities 4.1.3.1 Ageing Population Resulting in Increased Demand For High-End Pharmaceuticals 4.1.3.2 New Regulation Allowing for Expansion of the Regenerative Medicine Sector – Sakigake Reforms 4.1.3.3 Increased Trade Opportunities via the Trans-Pacific Partnership (TPP) 4.1.4 Threats 4.1.4.1 Possible Funding Issues Due to Demographics 4.1.4.2 Expanded Use of Biosimilars May Erode Pharmaceutical Market Revenues 4.2 Porter’s Five Forces Analysis of the Japanese Pharmaceutical Market 4.2.1 Rivalry Among Competitors [Medium] 4.2.2 Threat of New Entrants [Medium] 4.2.3 Power of Buyers [Medium] 4.2.4 Power of Suppliers [Medium] 4.2.5 Threat of Substitutes [Medium] 4.3 Leading Japanese Domestic Pharmaceutical Companies 4.3.1 Takeda 4.3.1.1 Litigation Regarding ACTOS in the US 4.3.2 Astellas Pharma 4.3.3 Otsuka Pharmaceuticals 4.3.4 Daiichi Sankyo 4.3.5 Eisai Co.
5. The Taiwanese Pharmaceutical Market 5.1 The Taiwanese Healthcare System 5.1.1 Costing and Healthcare Delivery 5.1.2 Health Technology Assessments 5.2 The Taiwanese Pharmaceutical Market 2014 and 2015 5.2.1 The Taiwanese Pharmaceutical Market Forecast, 2016-2026 5.3 The Taiwanese Pharmaceutical Market 2016-2026: Submarket Shares 5.4 The Taiwanese Generic Drugs Market 2014 and 2015 5.4.1 The Taiwanese Generic Drugs Market Forecast, 2016-2026 5.5 The Taiwanese Originator Drugs Market 2014 and 2015 5.5.1 The Taiwanese Originator Drugs Market Forecast, 2016-2026 5.6 The Taiwanese OTC Drugs Market 2014 and 2015 5.6.1 The Taiwanese OTC Drugs Market Forecast, 2016-2026 5.7 The Taiwanese Biosimilar Drugs Market 2014 and 2015 5.7.1 The Taiwanese Biosimilar Drugs Market Forecast, 2016-2026
6. Qualitative Analysis of the Taiwanese Pharmaceutical Market 6.1 SWOT Analysis of The Japanese Pharmaceutical Market, 2016-2026 6.1.1 Strengths 6.1.1.1 Stable Levels of NHI Funding 6.1.1.2 High Trust and Utilisation of Healthcare Facilities 6.1.1.3 Increasingly Aged Population 6.1.2 Weaknesses 6.1.2.1 Strong Presence of Traditional Medicines 6.1.2.2 Political Isolation and Lack of Bilateral Trade Deals 6.1.3 Opportunities 6.1.3.1 Ageing Population and Associated Pharmaceutical Demand Set to Increase 6.1.3.2 Newly Elected Government Promises Support for Pharmaceutical and Biotechnology Industries 6.1.3.3 The Promotion of Taiwan as a Destination for Medical Tourism 6.1.4 Threats 6.1.4.1 The Influence of China on Taiwanese International Relations 6.1.4.2 Rapid Growth of Pharmaceutical Markets in Rival Asian Countries 6.2 Porter’s Five Forces Analysis of the Taiwanese Pharmaceutical Market 6.2.1 Rivalry Among Competitors [Medium] 6.2.2 Threat of New Entrants [Low] 6.2.3 Power of Buyers [High] 6.2.4 Power of Suppliers [Low] 6.2.5 Threat of Substitutes [High] 6.3 Leading Taiwanese Pharmaceutical Companies 6.3.1 Standard Chem and Pharma Co. (SCP) 6.3.2 Chunghwa Chemical and Pharmaceutical Co. 6.3.3 Yung Shin Pharmaceutical Industry 6.3.4 TWi Biotechnology 6.3.5 OBI Pharmaceutical
7. The Korean Pharmaceutical Market 7.1 The Korean Healthcare System 7.1.1 Costing and Healthcare Delivery 7.2 The Korean Pharmaceutical Market 2014 and 2015 7.2.1 The Korean Pharmaceutical Market Forecast, 2016-2026 7.3 The Korean Pharmaceutical Market 2016-2026: Submarket Shares 7.4 The Korean Generic Drugs Market 2014 and 2015 7.4.1 Pharmaceutical Price Controls and Measures Being Implemented In South Korea 7.4.2 KORUS FTA: The Free Trade Agreement Between South Korea And The US 7.4.3 The Free Trade Agreement between Korea And The European Union 7.4.4 The Korean Generic Drugs Market Forecast, 2016-2026 7.5 The Korean Originator Drugs Market 2014 and 2015 7.5.1 The Korean Originator Drugs Market Forecast, 2016-2026 7.6 The Korean OTC Drugs Market 2014 and 2015 7.6.1 The Korean OTC Drugs Market Forecast, 2016-2026 7.7 The Korean Biosimilar Drugs Market 2014 and 2015 7.7.1 The Korean Biosimilar Drugs Market Forecast, 2016-2026
8. Qualitative Analysis of the Taiwanese Pharmaceutical Market 8.1 SWOT Analysis of The Japanese Pharmaceutical Market, 2016-2026 8.1.1 Strengths 8.1.1.1 Increasing Strength of Domestic Companies 8.1.1.2 Most Rapidly Ageing Population in the World 8.1.1.3 High Rate of OTC Use Among Population 8.1.2 Weaknesses 8.1.2.1 Funding for Healthcare Becoming Stretched and Pharmaceutical Pricing Pressure 8.1.2.2 Export Prices Based on Domestic Reimbursement 8.1.3 Opportunities 8.1.3.1 Ageing Population Will Result in Increased Expenditure 8.1.3.2 Increasing Level of International Sales for Domestic Companies 8.1.3.3 Korea has Registered Interest in Joining the TPP 8.1.4 Threats 8.1.4.1 Korea is Highly Reliant on Other Countries for its Economic Growth 8.1.4.2 Continued Pricing Pressure 8.2 Porter’s Five Forces Analysis of the Korean Pharmaceutical Market 8.2.1 Rivalry Among Competitors [Medium] 8.2.2 Threat of New Entrants [Medium] 8.2.3 Power of Buyers [High] 8.2.4 Power of Suppliers [Low] 8.2.5 Threat of Substitutes [High] 8.3 Leading Korean Pharmaceutical Companies 8.3.1 Daewoong Pharmaceutical Co. 8.3.2 Samsung Bioepis 8.3.3 Celltrion
9. Interviews 9.1 Interview with Sawai Pharmaceuticals, Tokyo, Japan 9.1.1 State of the Pharmaceutical Market in Japan 9.1.2 Current Challenges Facing the Market 9.1.3 Area with Highest Potential for Growth 9.1.4 Effect of Government Policy 9.1.5 Effect of the TPP 9.1.6 Opinions on the Taiwanese and Korean Pharmaceutical Markets
10. Conclusions 10.1 The East Asian Pharmaceutical Market 10.1.1 Ageing Population and Increased Healthcare Spending Pressure 10.1.2 Slowing Economic Growth 10.2 The Japanese Pharmaceutical Market 10.3 The Taiwanese Pharmaceutical Market 10.4 The Korean Pharmaceutical Market
List of Tables Table 1.1 Currency Exchange Rates, 2015 Table 2.1 Market Share (%) of the Global Pharmaceutical Market by Region, 2014 Table 2.2 The East Asian Pharmaceutical Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 3.1 The Japanese Pharmaceutical Market Forecast by Submarket: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 3.2 The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 3.3 The Japanese Originator Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 3.4 The Japanese OTC Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 3.5 The Japanese Biosimilar Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 4.1 SWOT Analysis of the Japanese Pharmaceutical Market, 2016-2026 Table 4.2 Takeda Pharmaceutical Company Overview Table 4.3 Astellas Pharma Overview Table 4.4 Otsuka Pharmaceuticals Overview Table 4.5 Daiichi Sankyo Overview Table 4.6 Eisai Co Overview Table 5.1 The Taiwanese Pharmaceutical Market Forecast by Submarket: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 5.2 The Taiwanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 5.3 The Taiwanese Originator Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 5.4 The Taiwanese OTC Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 5.5 The Taiwanese Biosimilar Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 6.1 SWOT Analysis of the Taiwanese Pharmaceutical Market, 2016-2026 Table 6.2 Standard Chem and Pharma Co. Overview Table 6.3 Chunghwa Chemical and Pharmaceutical Co. Overview Table 6.4 Yung Shin Pharmaceutical Industry Overview Table 6.5 TWi Biotechnology Overview Table 6.6 OBI Pharmaceutical Overview Table 7.1 The Korean Pharmaceutical Market Forecast by Submarket: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 7.2 The Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 7.3 The Korean Originator Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 7.4 The Korean OTC Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 7.5 The Korean Biosimilar Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026 Table 8.1 SWOT Analysis of the Korean Pharmaceutical Market, 2016-2026 Table 8.2 Daewoong Pharmaceutical Co. Overview Table 8.3 Samsung Bioepis Overview Table 8.4 Celltrion Overview Table 10.1 East Asian Pharmaceutical Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2026
List of Figures Figure 1.1 Key Markets within the East Asian Pharmaceutical Market Figure 2.1 Market Shares (%) of Pharmaceutical Market by Region, 2014 Figure 2.2 New Drug Regulatory Approval Pathway, Taiwan, 2016 Figure 3.1 The Japanese Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 3.2 The Japanese Pharmaceutical Market Submarkets by Revenue Share (%), 2014 Figure 3.3 The Japanese Pharmaceutical Market Submarkets by Revenue Share (%), 2020 Figure 3.4 The Japanese Pharmaceutical Market Submarkets by Revenue Share (%), 2026 Figure 3.5 The Japanese Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 3.6 The Japanese Originator Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 3.7 The Japanese OTC Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 3.8 The Japanese Biosimilar Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 4.1 A Comparison of the Updated and Previous Regulations Regarding Regenerative Medicine Testing in Japan Figure 4.2 Porter’s Five Forces Analysis of the Japanese Pharmaceutical Market, 2016-2026 Figure 5.1 The Taiwanese Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 5.2 The Taiwanese Pharmaceutical Market Submarkets by Revenue Share (%), 2014 Figure 5.3 The Taiwanese Pharmaceutical Market Submarkets by Revenue Share (%), 2020 Figure 5.4 The Taiwanese Pharmaceutical Market Submarkets by Revenue Share (%), 2026 Figure 5.5 The Taiwanese Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 5.6 The Taiwanese Originator Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 5.7 The Taiwanese OTC Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 5.8 The Taiwanese Biosimilar Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 6.1 Porter’s Five Forces Analysis of the Taiwanese Pharmaceutical Market, 2016-2026 Figure 7.1 The Korean Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 7.2 The Korean Pharmaceutical Market Submarkets by Revenue Share (%), 2014 Figure 7.3 The Korean Pharmaceutical Market Submarkets by Revenue Share (%), 2020 Figure 7.4 The Korean Pharmaceutical Market Submarkets by Revenue Share (%), 2026 Figure 7.5 The Korean Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 7.6 The Korean Originator Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 7.7 The Korean OTC Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 7.8 The Korean Biosimilar Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026 Figure 8.1 Porter’s Five Forces Analysis of the Korean Pharmaceutical Market, 2016-2026 Figure 10.1 East Asian Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Actavis Ambit Biosciences ASKA Pharmaceuticals Astellas Pharma Astex Pharmaceuticals Avanir Pharmaceuticals Biogen Idec Breckenridge Pharmaceutical Celltrion Chunghwa Chemical and Pharmaceutical Co. Daewoong Co. Ltd. Daewoong Pharmaceutical Co. Daiichi Sankyo Dainippon Sumimoto Pharma Dalim BioTech Eisai Co. Elyson Pharmaceuticals Fujifilm Corporation Fujisawa Pharmaceuticals Ilsung Pharmaceuticals JHL Biotech KMS Pharmaceutical LEO Pharma Merck MSD Novartis OBI Pharmaceutical Ocata Therapeutics OSI Pharmaceutical Otsuka Pharmaceuticals PharmaEngine Ranbaxy Samsung Samsung Bioepis Samsung Biologics Sandoz (Novartis) Sawai Pharmaceutical Standard Chem and Pharma Company Sun Pharmaceuticals Takeda Pharmaceutical Teva TWi Biotechnology Yamanouchi Pharmaceuticals Yung Shin Pharmaceutical Industry
Organisations Mentioned in the Report Academia Sinica Central Social Insurance Medical Council – Japan Democratic Progressive Party – Taiwan European Medicines Agency Joint Commission International Korean Food and Drug Administration Kuomingtang – Taiwan Ministry of Food and Drug Safety – Korea Ministry of Health and Welfare – Korea Ministry of Health and Welfare – Taiwan Ministry of Health, Labour and Welfare – Japan National Health Service – UK National Institute of Clinical Excellence – UK Pharmaceutical and Medical Devices Agency – Japan Taiwan Food and Drug Administration Trans-Pacific Partnership US Food and Drug Administration World Trade Organisation
Download sample pages
Complete the form below to download your free sample pages for East Asian Pharmaceutical Market 2016-2026
Download sample pages
Complete the form below to download your free sample pages for East Asian Pharmaceutical Market 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
